Transition/Switch to Dolutegravir
Among the 36 participants in the primary analysis population who were on an efavirenz-based regimen at enrolment, 16 of 17 (94.1%, 95% CI: 70.7 to 100.0) in the intervention arm transitioned/switched to dolutegravir by 24 weeks versus 14 of 19, (73.7%, 95% CI: 50.8 to 88.4, 